GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Rosetta Genomics Ltd (OTCPK:ROSGQ) » Definitions » LT-Debt-to-Total-Asset

Rosetta Genomics (Rosetta Genomics) LT-Debt-to-Total-Asset : 0.39 (As of Jun. 2017)


View and export this data going back to 2007. Start your Free Trial

What is Rosetta Genomics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Rosetta Genomics's long-term debt to total assests ratio for the quarter that ended in Jun. 2017 was 0.39.

Rosetta Genomics's long-term debt to total assets ratio increased from Mar. 2016 (0.00) to Jun. 2017 (0.39). It may suggest that Rosetta Genomics is progressively becoming more dependent on debt to grow their business.

Rosetta Genomics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Rosetta Genomics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rosetta Genomics LT-Debt-to-Total-Asset Chart

Rosetta Genomics Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.31

Rosetta Genomics Quarterly Data
Dec10 Mar11 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Jun17
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.01 0.01 0.31 0.39

Rosetta Genomics LT-Debt-to-Total-Asset Calculation

Rosetta Genomics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2016 is calculated as

LT Debt to Total Assets (A: Dec. 2016 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2016 )/Total Assets (A: Dec. 2016 )
=3.74/11.961
=0.31

Rosetta Genomics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2017 is calculated as

LT Debt to Total Assets (Q: Jun. 2017 )=Long-Term Debt & Capital Lease Obligation (Q: Jun. 2017 )/Total Assets (Q: Jun. 2017 )
=2.394/6.207
=0.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rosetta Genomics  (OTCPK:ROSGQ) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Rosetta Genomics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Rosetta Genomics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Rosetta Genomics (Rosetta Genomics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Rosetta Genomics Ltd (OTCPK:ROSGQ) » Definitions » LT-Debt-to-Total-Asset
Comparable Companies
BOM:526504 TSXV:MBI.H TEAR TSXV:AVCR NGM:LIFE B BOM:526546 BOM:541299 ASX:CTE TSXV:TELO ASX:LSH IDTA XSAT:ALPH BOM:526301 ABMC XLRM WAR:BMX XKRX:271850 WAR:IGN BOM:516110 SGX:505
Traded in Other Exchanges
N/A
Address
10 Plaut Street, Science Park, Rehovot, ISR, 76706
Website
http://www.rosettagenomics.com
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.
Executives
Sabby Management, Llc 10 percent owner 115 HIDDEN HILLS DR, SPICEWOOD TX 78669
Sabby Healthcare Volatility Master Fund, Ltd. 10 percent owner C/O SABBY MANAGEMENT, LLC, 10 MOUNTAINVIEW ROAD, SUITE 205, UPPER SADDLE RIVER NJ 07458